TruScreen Study Confirms AI Screening Outperforms Traditional Cytology in Cervical Cancer Detection

The latest update is out from TruScreen Group Ltd. ( (AU:TRU) ).

An independent 297-patient clinical study from Sichuan University has confirmed that TruScreen’s AI-enabled cervical cancer screening device, when combined with a high-risk HPV test, outperforms the traditional Thinprep cytology test plus HPV in detecting both low-grade and high-grade cervical lesions. The results, published in the Journal of Sichuan University and aligned with larger trials including the 14,982-woman COGA study, strengthen TruScreen’s case as a superior primary or co-testing solution versus cytology-based methods, support its strategic partnership with Chinese HPV test maker Dalton BioSciences, and bolster its positioning in global markets with constrained pathology infrastructure.

The growing body of evidence, now exceeding 30 studies and 40,000 women, underscores the clinical and operational advantages of TruScreen’s real-time, point-of-care approach that avoids reliance on cytology labs and specialist cytologists. This latest validation is likely to enhance the company’s credibility with health authorities and screening program designers, potentially accelerating adoption of TruScreen-based protocols in China and other regions seeking more scalable, technology-driven cervical cancer screening solutions.

More about TruScreen Group Ltd.

TruScreen Group Limited is a dual-listed NZX and ASX medical technology company focused on AI-enabled cervical cancer screening. Its core product is a real-time, point-of-care opto-electronic device that can be used with high-risk HPV tests, targeting markets where access to cytology laboratories and specialist pathologists is limited.

Average Trading Volume: 843,359

Technical Sentiment Signal: Sell

Current Market Cap: A$10.02M

For a thorough assessment of TRU stock, go to TipRanks’ Stock Analysis page.